Aspects of etiopathogenesis and therapy of vitiligo
DOI:
https://doi.org/10.11606/issn.1679-9836.v99i3p278-285Keywords:
Vitiligo, Autoimmunity, Repigmentation, Drug therapy, Phototherapy, Cosmetic, Surgery, Tissue graftAbstract
Introduction: Vitiligo is a chronic skin disease characterized by cutaneous depigmentation, being associated with aesthetic disfiguration and considerable psychological discomfort, representing great challenges in terms of dermatological care. Main Objective: To address the etiopathogenic aspects of vitiligo, as well as to present current therapeutic options for disease management. Method: Narrative bibliographic review using the electronic Pubmed database (US National Library of Medicine). The research was carried out in 2018, using the following identifiers in Health Sciences: vitiligo, cosmetic camouflage and vitiligo, treatment and vitiligo, physiopathology and vitiligo, immunopathology and vitiligo. We selected 26 researches published in the period from 2011 to 2018 that presented contents related to the objectives of this study. Result: Vitiligo is developed by the association of a genetic predisposition and exposure to environmental factors. The treatment aims to limit the progression of the disease, promote repigmentation of the affected areas and prevent relapses; It can be divided into clinical, aesthetic and surgical. Topical, systemic, phototherapy and recent immunobiological medicines are clinical treatments. The aesthetic treatment is represented by cosmetic camouflage and the surgical one is indicated for those who present stable disease not responsive to clinical therapy. Conclusion: Treatment is usually performed by the association of techniques, which is why it should be individualized for each patient. Early initiation of treatment is associated with a more favorable prognosis of the disease. It is of extreme importance not to neglect it in addition to knowing therapeutic innovations, considering the potential societal stigmatization of the disease, as a result improving clinical practice and quality of life of patients.
Downloads
References
Boniface K, Seneschal J, Picardo M, Taïeb A. Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. Clin Rev Allergy Immunol. 2018;54(1):52-67. doi: 10.1007/s12016-017-8622-7.
Speeckaert R, van Geel N. Vitiligo: an update on pathophysiology and treatment options. Am J Clin Dermatol. 2017;18(6):733-44. doi: 10.1007/s40257-017-0298-5.
Szabo I, Brandão ER. “Mata de tristeza!”: representações sociais de pessoas com vitiligo atendidas na farmácia universitária da Universidade Federal do Rio de Janeiro, Brasil. Interface Commun Heal Educ. 2016;20(59):953-65. doi: 10.1590/1807-57622015.0596.
Rashighi M, Harris JE. Vitiligo pathogenesis and emerging treatments. Dermatol Clin. 2017;35(2):257-65. http://dx.doi.org/10.1016/j.det.2016.11.014
Passeron T. Medical and maintenance treatments for vitiligo. Dermatol Clin. 2017;35(2):163-70. doi: 10.1016/j.det.2016.11.007.
Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, et al. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(7):666-74. doi: 10.1001/jamadermatol.2017.0002.
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017;77(1):17-29. http://dx.doi.org/10.1016/j.jaad.2016.11.010.
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017;77(1):1-13. http://dx.doi.org/10.1016/j.jaad.2016.10.048.
Patel S, Rauf A, Khan H, Meher BR, Hassan SSU. A holistic review on the autoimmune disease vitiligo with emphasis on the causal factors. Biomed Pharmacother. 2017;92:501-8. doi: 10.1016/j.biopha.2017.05.095.
Padilla-España L, Ramírez-López B, Fernández-Sánchez E. Utilidad del maquillaje terapéutico en niños con vitíligo en un taller coordinado por enfermería de dermatología. Enferm Clin. 2014;24(3):196-9. doi: 10.1016/j.enfcli.2014.03.001.
Cupertino F, Niemeyer-Corbellini JP, Ramos-e-Silva M. Psychosomatic aspects of vitiligo. Clin Dermatol. 2017;35(3):292-7. http://dx.doi.org/10.1016/j.clindermatol.2017.01.001
Birlea SA, Goldstein NB, Norris DA. Repigmentation through Melanocyte regeneration in vitiligo. Dermatol Clin. 2017;35(2):205-18. doi: 10.1016/j.det.2016.11.015.
Wong R, Lin AN. Pharmacology and therapeutics efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol. 2013;52(4):491-6. doi: 10.1111/j.1365-4632.2012.05697.x.
Singh RK, Lee KM, Vujkovic-cvijin I, Ucmak D, Farahnik B, Abrouk M, et al. The role of IL-17 in vitiligo: a review. Autoimmun Rev. 2016;15(4):397-404. doi: 10.1016/j.autrev.2016.01.004.
Bhardwaj S, Bhatia A, Kumaran MS, Parsad D. Role of IL-17A receptor blocking in melanocytes survival: A strategic intervention against vitiligo. Exp Dermatol. 2019;28(6):682-9. doi: 10.1111/exd.13773.
Rashighi M, Harris JE. Interfering with the IFN-gamma/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med. 2015;3(21):343. doi: 10.3978/j.issn.2305-5839.2015.11.36.
Le Poole IC, Mehrotra S. Replenishing regulatory T cells to halt depigmentation in vitiligo. J Investig Dermatology Symp Proc. 2017;18(2):S38-45. doi: 10.1016/j.jisp.2016.10.023.
Esmat S, Hegazy RA, Shalaby S, Chu-Sung Hu S, Lan CCE. Phototherapy and combination therapies for vitiligo. Dermatol Clin. 2017;35(2):171-92. http://dx.doi.org/10.1016/j.det.2016.11.008.
Ibbotson SH. A Perspective on the use of NB-UVB phototherapy vs. PUVA photochemotherapy. Front Med. 2018;5(July):1-8. doi: 10.3389/fmed.2018.00184.
Yazdani Abyaneh M, Griffith RD, Falto-Aizpurua L, Nouri K. Narrowband ultraviolet B phototherapy in combination with other therapies for vitiligo: mechanisms and efficacies. J Eur Acad Dermatology Venereol. 2014;28(12):1610-22. doi: 10.1111/jdv.12619.
Antonio CR, Antonio JR, De Vita Marques AM. Excimer laser no tratamento do vitiligo em 123 pacientes: estudo retrospectivo. Surg Cosmet Dermatol. 2011;3(3):213-8. Disponível em: http://www.surgicalcosmetic.org.br/detalhe-artigo/148/Excimer-Laser-no-tratamento-do-vitiligo-em-123-pacientes--estudo-retrospectivo.
Kaliyadan F, Kumar A. Camouflage for patients with vitiligo. Indian J Dermatol Venereol Leprol. 2012;78(1):8.. doi: 10.4103/0378-6323.90940.
Salsberg JM, Weinstein M, Shear N, Lee M, Pope E. Impact of cosmetic camouflage on the quality of life of children with skin disease and their families. J Cutan Med Surg. 2016;20(3):211-5. doi: 10.1177/1203475415595175.
Mohammad TF, Hamzavi IH. Surgical therapies for vitiligo. Dermatol Clin. 2017;35(2):193-203. http://dx.doi.org/10.1016/j.det.2016.11.009.
Vakharia PP, Lee DE, Khachemoune A. Efficacy and safety of noncultured melanocyte-keratinocyte transplant procedure for vitiligo and other leukodermas: a critical analysis of the evidence. Int J Dermatol. 2018;57(7):770-5. doi: 10.1111/ijd.13895.
Nahhas AF, Mohammad TF, Hamzavi IH. Vitiligo surgery: shuffling melanocytes. J Investig Dermatol Symp Proc. 2017;18(2):S34-7. https://doi.org/10.1016/j.jisp.2017.01.001.
